Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma (Q38026916)

27 August 2017

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma (English)

1 reference

27 August 2017

1 reference

5

1 reference

27 August 2017

G V Long

7

0 references

Pablo Fernandez-Peñas

object named as

P Fernandez-Peñas

8

0 references

author name string

R M Anforth

1

1 reference

27 August 2017

T C M P Blumetti

2

1 reference

27 August 2017

R F Kefford

3

1 reference

27 August 2017

R Sharma

4

1 reference

27 August 2017

S Kossard

6

1 reference

27 August 2017

language of work or name

English

0 references

publication date

5 October 2012

1 reference

British Journal of Dermatology

27 August 2017

1 reference

27 August 2017

167

1 reference

27 August 2017

5

1 reference

27 August 2017

1153-1160

1 reference

Cutaneous melanoma in the era of molecular profiling

27 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11155.X

Improved survival for stage IV melanoma from an unknown primary site

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11155.X

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11155.X

BRAF signaling and targeted therapies in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11155.X

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11155.X

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11155.X

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11155.X

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11155.X

RAF inhibition and induction of cutaneous squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11155.X

Body-site distribution of skin cancer, pre-malignant and common benign pigmented lesions excised in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11155.X

Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11155.X

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11155.X

Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11155.X

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11155.X

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11155.X

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11155.X

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11155.X

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11155.X

Immunohistochemical comparison of p16 expression in actinic keratoses and squamous cell carcinomas of the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11155.X

Diagnostic utility of p16INK4a: a reappraisal of its use in cervical biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11155.X

Loss of expression of the p16 gene is frequent in malignant skin tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11155.X

Unraveling the prognostic heterogeneity in patients with advanced melanoma between Australia (OZ) and the United States (US): Preliminary report of the PHAMOUS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11155.X

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11155.X

BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11155.X

10.1111/J.1365-2133.2012.11155.X

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference